Katsumi Kitagawa, PhD, principal investigator, Center for Childhood Cancer and Blood Diseases, and colleagues are studying Sgt1 inhibitors for their capacity as anti-cancer drugs. Sgt1 is a protein required for several essential cellular activities.
Their research findings demonstrate that Sgt1 deletion suppresses p53-induced tumor development. Furthermore, their data indicate that SGT1 is a novel oncogene; it is highly expressed in several tumors including pediatric tumors such as rhabdomyosarcoma and Ewing tumors. Further research is planned to investigate the effectiveness of Sgt1 inhibitors as anti-cancer drugs, particularly for Sgt1-overexpressing pediatric tumors.
Contact: Katsumi Kitagawa, PhD